louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01303848: Circadian Rhythm of Blood Lactate
Official title: Circadian Rhythm of Blood Lactate, Lipid Transferproteins and Genetic Markers (PPARs, CLOCK, Bmal1)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: Blood lactate
Lipid transfer proteins
Lactate
PLTP
CETP
PPARs
CLOCk
Bal1
Lead sponsor: Martin-Luther-Universität Halle-Wittenberg
Sponsor class: OTHER
Collaborators: name: State University of New York - Downstate Medical Center
First posted: 2011-02-25
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 30 healthy probands

Brief summary: To elucidate whether blood lactate, lipid transfer proteins and PPARs/CLOCK/Bal1 have a circadian rhythm

Detailed description: Blood will be drawn fasting and then every hour over a period of 24 hours in 30 healthy probands.

Eligibility criteria: Inclusion Criteria:

* Age between 18 and 40 years old

Exclusion Criteria:

* Inability/unwilling to give written informed consent
* Chronic disease

Primary outcomes:
measure: Circadian rhythm of blood lactate
timeFrame: 5 months
Secondary outcomes:
measure: Circadian rhythm of Lipid transfer proteins
timeFrame: 5 months
measure: Circadian rhythm of PPARs, CLOCK and Bal1
timeFrame: 5 months
Other outcomes:
Locations:
city: Halle (Saale)
country: Germany
facility: University Clinic Halle, Martin Luther-University Halle-Wittenberg
Study officials:
affiliation: Department of Medicine III, University Clinic Halle, Martin Luther-University Halle-Wittenberg
name: Axel Schlitt, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02902848: Evaluation of the Validity of the Prothrombin Time Internation Normalised Ratio (PT/INR) Measured at the point-of Care on the Arterial Bloodline of Haemodialysis Extracorporeal Blood Flow
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Haemodialysis
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2016-09-16
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population of the study is the patients under haemodialysis treatment, who need INR monitoring

Brief summary: The purpose of this study is to evaluate the INR value of hemodialyzed patient coagulation state (prothrombin time) measured inside the therapeutical zone and thanks to a portable monitor. The values obtained at the point of care will be compared to the standard biological assessment.


Eligibility criteria: Inclusion Criteria:

* Age \> 18
* Haemodialyzed patient whose INR needs to be monitored
* Patient not objecting to participate in the study

Primary outcomes:
measure: correlation ratio between point-of-care PT/INR value and standard laboratory assessement
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHU Brest
Study officials:
References:
Clinical trial NCT00608348: Sympathetic Nerve Activity During Hypoglycemia and Exercise
Official title: Sympathetic Nerve Activity During Hypoglycemia and Exercise
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Keywords: exercise
hypoglycemia
sympathetic nerve activity
Lead sponsor: Vanderbilt University
Sponsor class: OTHER
First posted: 2008-02-06
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL

Brief summary: The purpose of this study is to determine if either hypoglycemia or exercise cause differential responses in muscle and skin sympathetic nerve activity.

Detailed description: The body has defensive responses to correct low blood sugar (hypoglycemia). A vital component of this response is release of glucagon and activation of the sympathetic nervous system, which provides the means for raising blood glucose levels towards normal. We can measure circulating hormones indicating the level of these responses, but additionally, sympathetic nervous system responses can be measured directly. We can measure the sympathetic nerve activity that controls blood flow to muscles (MSNA) and blood flow and sweating to skin (SSNA). The purpose of this study is to determine if either hypoglycemia or exercise cause differential responses in muscle and skin sympathetic nerve activity. We would also like to determine what the sympathetic response is to cycling exercise with insulin and normal blood sugar. Therefore, we would like to test the sympathetic responses to insulin with normal blood glucose, hypoglycemia, and during exercise bouts and normal blood glucose, with or without insulin.

Eligibility criteria: Inclusion Criteria:

* 36 Healthy male and female subjects (18 males and 18 females) aged 18-40 yr
* All potential volunteers will have routine blood test to screen for hepatic, renal, and hematological abnormalities
* Body mass index ≤30kg · m-2
* Normal bedside autonomic function
* Female volunteers of childbearing potential will undergo HCG pregnancy test at screening and again on the study day.

Exclusion Criteria:

* Pregnant women
* Subjects unable to give voluntary informed consent
* Subjects on anticoagulant drugs or anemic
* Subjects with a recent medical illness
* Subjects with a history of hypertension, heart disease or cerebrovascular disease
* Subjects with known liver or kidney disease
* Subjects with recent weight loss or consuming a low carbohydrate diet

Primary outcomes:
measure: Muscle sympathetic nerve activity
timeFrame: 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University
state: Tennessee
Study officials:
affiliation: Vanderbilt University
name: Stephen N. Davis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00327548: Use of Guided Imagery for Functional Abdominal Pain in Children:
Official title: Treatment of Functional Abdominal Pain in Children:Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Functional Abdominal Pain
Lead sponsor: Children's Mercy Hospital Kansas City
Sponsor class: OTHER
Collaborators: name: University of Arizona
First posted: 2006-05-18
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of the study is to evaluate the effectiveness of relaxation, with or without guided imagery, for treating children with functional abdominal pain. The study will evaluate a child's ability to decrease the amount of pain with these techniques to allow continuation of normal daily activities at home and at school. The hypothesis is that these relaxation techniques will help decrease reports of abdominal pain and improve levels of activity.


Eligibility criteria: Inclusion Criteria:

at least 3 episodes of abdominal pain over the previous 3 months normal complete blood count, sedimentation rate, urinalysis stable on current medications English speaking -

Exclusion Criteria:

unwillingness to participate chronic gastrointestinal disease cognitive-developmental delay major dissociative disorder

-

Primary outcomes:
measure: Level of pain
measure: number of days of pain
measure: missed activities
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Arizona
name: Fayez K Ghishan, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00481130: Alport Syndrome Treatments and Outcomes Registry
Official title: Alport Syndrome Treatments and Outcomes Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Alport Syndrome
Keywords: Alport Syndrome
x linked
autosomal dominant Alport syndrome
glomerular basement membrane
hereditary nephritis
familial benign haematuria
type IV collagen
hereditary nephritis with neurosensory deafness
vison loss
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2007-06-01
Enrollment: 1000
Sex: ALL
Minimum age (years): 0
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: FAMILY_BASED
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Family and individual history of a diagnosis of Alport syndrome

Brief summary: ASTOR's primary purpose is to enroll families and patients with a history of Alport syndrome in a central registry. The information we gather will be used as a basis for studies designed to test potential treatments for Alport syndrome. ASTOR also aims to provide patients, families and physicians with the most up-to-date information about Alport syndrome.

Detailed description: The University of Minnesota's Department of Pediatrics has created the Alport Syndrome Treatments and Outcomes Registry (ASTOR). ASTOR's primary purpose is to enroll families and patients with a history of Alport syndrome in a central registry. The information we gather will be used as a basis for studies designed to test potential treatments for Alport syndrome. ASTOR also aims to provide patients, families and physicians with the most up-to-date information about Alport syndrome.

You can help doctors learn more about Alport syndrome and test possible treatments for the disease by enrolling in ASTOR. Since Alport syndrome is a rare disease it is essential for ASTOR to enroll as many patients as possible. Together, you and others facing the challenges of Alport syndrome can provide valuable information that will help doctors better understand the disease and in turn, help patients with Alport syndrome now and in the future.

Eligibility criteria: Inclusion Criteria: History of a diagnosis of Alport syndrome, Family or individuals need to be able to comprehend the consent and HIPAA forms written in the English language.

Exclusion Criteria: Uncertain diagnosis of Alport syndrome.

Primary outcomes:
measure: Data Collection: natural history study
timeFrame: Ongoing
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota, Department of Pediatrics
name: Clifford Kashtan, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kashtan CE, Gross O. Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatr Nephrol. 2021 Mar;36(3):711-719. doi: 10.1007/s00467-020-04819-6. Epub 2020 Nov 6.
Clinical trial NCT03391830: Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy
Official title: Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy. Randomised Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Contrast-induced Nephropathy
Statin
Ascorbic Acid
AKI
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2018-01-05
Enrollment: 250
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To evaluate the benefit for statin use in prevention of of CI-AKI after computed tomography urogram (CTU).


Eligibility criteria: Inclusion Criteria:

* Planned computed tomography urogram (CTU)
* Statin naive, or not on statin treatment for at least 14 day

Exclusion Criteria:

* History of liver disease or elevated serum transaminases
* History of rhabdomyolysis or elevated creatinine kinase
* History of iodinated CM use within 14 days before randomization
* History of N-acetylcysteine, metformin or nonsteroidal anti-inflammatory drugs use within 48 hours of the procedure.
* History of hypersensitivity reaction to contrast media
* Pregnancy or lactation
* Acute renal failure
* End-stage renal disease requiring dialysis
* Cardiogenic shock or pulmonary edema
* Multiple myeloma

Primary outcomes:
measure: Contrast Induced-Acute Kidney Injury
timeFrame: 3 days
Secondary outcomes:
measure: long-term Renal function by estimated GFR
timeFrame: 30 days
Other outcomes:
Locations:
city: Mansourah
country: Egypt
facility: Urology and Nephrology Center
state: Aldakahlia
Study officials:
affiliation: Urology and nephrology center
name: Yasser Othman, MD
role: STUDY_CHAIR
References:
Clinical trial NCT01350830: Preperitoneal Versus Pre-trasversalis Hernia Repair
Official title: Early and Late Results of Transinguinal Preperitoneal Patch Repair Versus Anterior Pre-Trasversalis Mesh Repair. A Randomised Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Direct Inguinal Hernia
Indirect Inguinal Hernia
Keywords: inguinal hernia
groin hernia
chronic pain
mesh repair
Lead sponsor: San Bonifacio Hospital
Sponsor class: OTHER
First posted: 2011-05-10
Enrollment: 253
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chronic pain rate is from 0 to 50% after prosthetic groin hernia repair. We compared two anterior technique positioning the mesh in the pre-trasversalis space vs preperitoneal space to assess any differences in term of chronic pain and early and late complications

Detailed description: Chronic pain is evaluated in all presenting types (achy, dull, etc.) moreover foreing body sensation, wall stiffness, paresthesia and numbness are controlled in each patients. Limiting of daily, working, sport and sexual activities (disejaculation) are reported as well.

Eligibility criteria: Inclusion Criteria:

* 18 years older

Exclusion Criteria:

* recurrent inguinal hernia
* previous low abdominal operation

Primary outcomes:
measure: chronic pain rate
timeFrame: 6 months
Secondary outcomes:
measure: recurrence rate
timeFrame: 2 years
Other outcomes:
Locations:
city: San Bonifacio
country: Italy
facility: San Bonifacio Hospital
state: VR
Study officials:
affiliation: Azienda Ulss 20 Verona
name: Francesco Orcalli, M.D.
role: STUDY_DIRECTOR
References:
citation: Pelissier EP. Inguinal hernia: preperitoneal placement of a memory-ring patch by anterior approach. Preliminary experience. Hernia. 2006 Jun;10(3):248-52. doi: 10.1007/s10029-006-0079-1. Epub 2006 Apr 21.
citation: Pelissier EP, Monek O, Blum D, Ngo P. The Polysoft patch: prospective evaluation of feasibility, postoperative pain and recovery. Hernia. 2007 Jun;11(3):229-34. doi: 10.1007/s10029-007-0203-x. Epub 2007 Feb 15.
Clinical trial NCT03042130: Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency
Official title: Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Heart Failure
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2017-02-03
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients.

Detailed description: Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The control group will receive standard of care alone. The study will test for the effects of the additional IV iron on the symptoms, clinical picture and quality of life of the treated patients. The parameters that will be measured will include clinical, lab, echo, and quality of life questionnaires.

Eligibility criteria: Inclusion Criteria:

* Heart failure grade 3-4
* Heart echo EF\< 40% (ejection fraction)
* Hb \> 10 mg/dL
* Iron\> 50 mic/dL
* Iron/ transferrin rate \> 20%

Exclusion Criteria:

* Infection
* Acute ischemia
* Patients that didn't receive the standard of care during 3 days before investigational product administration
* Hemochromatosis
* Known allergy to one of the products of the investigational product.
* Macrocytic anemia
* Iron excess
* Pregnant women
* Mentally disabled patients which can't give their concent properly.

Primary outcomes:
measure: Functioning improvement
timeFrame: 5 days after second administration
measure: Quality of life improvement
timeFrame: 5 days after second administration
measure: Functioning improvement
timeFrame: 1 month after second administration
measure: Quality of life improvement
timeFrame: 1 month after second administration
Secondary outcomes:
Other outcomes:
Locations:
city: Tel-Aviv
country: Israel
facility: Department of internal medicine A
Study officials:
affiliation: Physician - Internal Medicine
name: Howard Oster, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06047730: Clinical Effect Evaluation of Laparoscopic Surgery for Ovarian Benign Tumors by Different Approaches
Official title: Clinical Effect Evaluation of Laparoscopic Surgery for Ovarian Benign Tumors by Different Approaches
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Laparoscope
Malignant Ovarian Tumor
Single-site Surgery
Keywords: Transumbilical laparoendoscopic single-site surgery,Giant malignant ovarian tumor
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2023-09-21
Enrollment: 173
Sex: FEMALE
Minimum age (years): 10
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: nothing

Brief summary: Main purpose: To compare the intraoperative and postoperative recovery of laparoscopic surgery for ovarian benign tumors through different approaches; Secondary objective: Will vNOTES increase the risk of cesarean section during pregnancy and affect the quality of sexual life after surgery.


Eligibility criteria: Inclusion Criteria:

Preoperative consideration was for benign ovarian tumors requiring surgical treatment.

Exclusion Criteria:

* (1) Ovarian malignant tumor or borderline tumor was considered before surgery or proved during surgery. (2) Severe endometriosis, previous severe pelvic inflammation, peritonitis, and other serious pelvic adhesions are considered. (3) Pregnancy status. (4) Postoperative follow-up is not convenient and lost visitors.

Primary outcomes:
measure: peroperative bleeding
timeFrame: during the operation time
Secondary outcomes:
measure: postoperative exhaust time
timeFrame: within 3 days after operation
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University
state: Shandong
Study officials:
References:
Clinical trial NCT00513630: Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease
Official title: Phase 4 Study on the Prognosis and Effect of Anti-diabetic Drugs on Type-2 Diabetes Mellitus With Coronary Artery Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Type 2 Diabetes
Coronary Artery Disease
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Sponsor class: OTHER
First posted: 2007-08-08
Enrollment: 304
Sex: ALL
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to explore the recurrence risk of cardiovascular events in patients with type 2 diabetes mellitus and coronary heart disease after different antidiabetic drug therapy (glipizide or metformin) by using an double-blind, randomized, parallel control and prospective study

The end point of this study is:

1. follow up 3yr
2. recurrence of cardiovascular event
3. death caused by other reasons such as stroke, uremia, blindness and amputation


Eligibility criteria: Inclusion Criteria:

* Coronary heart disease
* Type 2 diabetes

Exclusion Criteria:

* Severe organ dysfunction, psychopathy, infection, neutropenia
* Congenital heart disease, rheumatic heart disease, severe arrhythmia, myocardiopathy

Primary outcomes:
measure: Composite of cardiovascular events which were defined as death from a cardiovascular cause, death from any cause, nonfatal myocardial infarction, nonfatal stroke or arterial revascularization
Secondary outcomes:
measure: New or worsening angina
measure: new or worsening heart failure
measure: new critical cardiac arrhythmia
measure: new peripheral vascular events
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Jiao Tong University School of Medicine
Study officials:
affiliation: Shanghai Jiao Tong University School of Medicine
name: Guang Ning, MD. PHD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, Zou D, Wang D, Li H, Liu C, Wu G, Shen J, Zhu D, Wang W, Shen W, Ning G; SPREAD-DIMCAD Investigators. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013 May;36(5):1304-11. doi: 10.2337/dc12-0719. Epub 2012 Dec 10.